75岁董事长，赤膊秀肌肉！工作人员：一点都没P，董事长每天早上5点健身

Core Viewpoint - The recent advertisement featuring Kelong Pharmaceutical's chairman, Liu Gexin, showcasing his physique at the age of 75 has sparked discussions, with mixed opinions from the public regarding its authenticity and effectiveness compared to celebrity endorsements [1][4]. Summary by Sections Advertisement and Product Promotion - Liu Gexin, the chairman of Kelong Pharmaceutical, promotes the company's ergothioneine capsules, emphasizing their potential anti-aging benefits and claiming that the product's effectiveness in eliminating free radicals is 10-30 times greater than traditional ingredients like Vitamin C and Coenzyme Q10 [5]. - The capsules are priced at 1499 yuan for a bottle containing 60 capsules, and the advertisement has passed regulatory review, set to be broadcast soon [5]. Product Background and Market Potential - Ergothioneine is a rare amino acid with antioxidant, cell protection, and anti-inflammatory properties, showing promise in disease prevention and treatment, including neuroprotection and potential benefits for sleep and memory enhancement [8]. - The product is relatively uncommon in oral form, with more prevalence in skincare products [8]. Financial Performance - Kelong Pharmaceutical reported a 29.42% year-on-year decline in revenue for Q1 2025, totaling 4.39 billion yuan, and a 43.07% drop in net profit to 584 million yuan [10]. - The company's core infusion business continues to face challenges due to centralized procurement policies, leading to a significant revenue decline in its synthetic biology segment [10]. Strategic Direction - In light of declining financial performance, Kelong Pharmaceutical is venturing into the health and wellness sector, with Liu Gexin personally endorsing the high-end health products as a strategy to create a new growth avenue [12]. - Kelong Yongnian, a subsidiary focused on health products, was established in 2024 and is fully controlled by Kelong Pharmaceutical [12]. Leadership and Market Position - Liu Gexin, known as the "King of Infusion," has significant influence in the industry, with Kelong Pharmaceutical holding a leading market share of 22.1% in the infusion market as of 2008 [15]. - The chairman's family controls three publicly listed companies, with a combined market value exceeding 549 billion yuan [13]. Industry Trends - The trend of entrepreneurs endorsing their own products is becoming more common, with examples including Vanke's Wang Shi and Gree's Dong Mingzhu, indicating a shift towards personal branding in marketing strategies [16].